Compare Boeing Co (BA) vs DexCom, Inc. (DXCM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Boeing Co vs DexCom, Inc. — how do they compare? Boeing Co trades at $219.35 (market cap $171.15B), while DexCom, Inc. trades at $74.77 (market cap $28.60B). The key difference: Boeing Co is far larger — about 6× DexCom, Inc.'s market cap, and Boeing Co pays a 0.03% dividend while DexCom, Inc. pays none. Which is the better fit depends on your goals.
| BA | DXCM | |
|---|---|---|
Market Cap | $171.15B | $28.60B |
Volume | 7,591,579 | — |
Sector | Industrials | Health |
52-Week High | $252.15 | $89.53 |
52-Week Low | $179.12 | $54.84 |
Enterprise Value | $197.46B | $27.57B |
Dividend Yield | 0.03% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Boeing (BA) trades at $215.51, down 3.05% on the day, amid a bearish technical signal. The stock shows mixed fundamentals with a high P/E of 85.18 but improving revenue and net income, reaching $89.46B and $2.24B in 2025, respectively. Recent news highlights potential order wins, including discussions with Riyadh Air for additional 787s, while technical indicators point to support near $209.
Outlook remains cautiously optimistic with a consensus price target of $268.33, implying 24.5% upside, but risks include volatile cash flows, high debt, and ongoing operational challenges. Analyst sentiment is bullish with 66.7% buy ratings, though investors should monitor execution on delivery targets and margin improvements.
DXCM trades at $76.35, up 1.85% today, with strong technical momentum and bullish moving average signals. The company demonstrates robust fundamentals with 17.93% net income margin and consistent earnings beats. Recent regulatory approvals for G7 15-day CGM in Canada and pediatric clearance for Stelo OTC system highlight growth catalysts. Revenue growth accelerated to $4.66 billion in 2025, up from $4.0 billion in 2024.
DXCM presents a compelling growth story with expanding CGM market access and strong analyst support (80% buy ratings). Key risks include GLP-1 adoption impact on core market and execution of Type 2 non-insulin patient expansion. The stock trades at a premium valuation (P/E 32.76) but offers upside to consensus target of $83.78. Near-term focus on Q2 2026 earnings release July 30.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Boeing Co
The Boeing Company, together with its subsidiaries, develops, produces, and markets commercial jet aircraft, as well as provides related support services to the commercial airline industry worldwide. The Company also researches, develops, produces, modifies, and supports information, space, and defense systems, including military aircraft, helicopters and space and missile systems.
Read more on BA →About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →
